Key Points – KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line Phase 2b data expected by the end of 2026 and potential Phase 3 initiation around mid-2027.
The asthma Phase 2b trial is also enrolling, with results expected in late 2027. – Kymera’s wholly owned KT-579 IRF5 degrader remains on track to report Phase 1 data in the fourth quarter of 2026 and enter a lupus proof-of-concept study shortly afterward, targeting significant unmet needs in autoimmune disease. – The company ended June with approximately $1.5 billion in cash, cash equivalents and investments, providing a runway into 2029
Second-quarter collaboration revenue reached $65 million, including a $20 million Sanofi milestone and a $45 million Gilead-related option exercise fee. – Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer Nello Mainolfi said the accelerated enrollment reflected investigator and patient interest in a once-daily oral treatment, as well as the company’s clinical execution. The placebo-controlled BROADEN2 study is evaluating three doses of KT-621, a STAT6 degrader, in atopic dermatitis.
The primary endpoint is the percentage change from baseline in EASI score at week 16, while secondary measures include EASI-50, EASI-75, Investigator’s Global Assessment, pruritus scores and safety. – Analysts Can’t Get Enough of These Little-Known Biopharma Stocks Mainolfi said the company sought to maintain trial quality and enroll patients with appropriate disease severity despite the faster-than-expected recruitment. He said Kymera expects its results to fall “in that ballpark” of prior dupilumab atopic dermatitis studies, while noting…